Table 1 Basic characteristics of included studies
No | Trial | Year | Article(s) | Phase | Study design | Population (Intervention/Control) | Disease state (newly-diagnosed/recurrent) | Intervention arm | Control arm |
|---|---|---|---|---|---|---|---|---|---|
1. | VELIA | 2019 | Coleman et al. (2019) [33] | III | randomized, double-blind, placebo- controlled | 1,140 (382/383/375) | Newly-diagnosed | PBC + Veliparib 150 orally twice a day + Veliparib 300–400 mg orally twice day as maintenance (382) or PBC + Veliparib 150 mg orally twice a day + placebo as maintenance | PBC + placebo daily + placebo as maintenance |
2. | ARIEL 3 | 2017 | III | randomized, double-blind, placebo- controlled | 564 (375/189) | Recurrent | Rucaparib 600 mg orally twice a day | Placebo | |
3. | Study 19 | 2012 | Ledermann et al. (2012, 2014, 2016) [36,37,38]; Friedlander et al. (2018) [39] | II | randomized, double-blind, placebo- controlled | 265 (136/129) | Recurrent | Olaparib 400 mg orally twice a day | Placebo |
4. | PRIMA | 2019 | González et al. (2019) [40] | III | randomized, double-blind | 733 (487/246) | Newly-diagnosed | Niraparib 300/200 mg orally twice a day | Placebo |
5. | ICEBERG 3 | 2012 | Kaye et al. (2012) [41] | II | randomized, open-label | 65 (32/33) | Recurrent | Niraparib 400 mg orally twice a day | PLD |
6. | NOVA | 2016 | III | randomized, double-blind, placebo- controlled | 553 (372/181) | Recurrent | Niraparib 300 mg orally daily | Placebo | |
7. | SOLO 1 | 2018 | III | randomized, double-blind, placebo- controlled | 391 (260/131) | Newly-diagnosed | Olaparib 300 mg orally twice a day | Placebo | |
8. | Oza 2015 | 2015 | Oza et al. (2015) [46] | II | randomized, open-label | 162 (81/81) | Recurrent | PBC + Olaparib 200 mg orally twice a day + Olaparib 400 mg orally twice a day as maintenance | PBC |
9. | SOLO 3 | 2020 | Penson et al. (2020) [47] | III | randomized, open-label | 266 (178/88) | Recurrent | Olaparib 300 mg orally twice a day | Single agent chemotherapy |
10. | SOLO 2 | 2020 | Pujade-Lauraine et al. (2017) [48]; Poveda et al. (2021) [49] | III | randomized, double-blind | 295 (196/99) | Recurrent | Olaparib 300 mg orally twice a day | Placebo |
11. | SOLO 1 China | 2021 | Wu L, et al. (2021) [50] | III | randomized, double-blind, placebo- controlled | 64 (44/20) | Newly-diagnosed | Olaparib 300 mg orally twice a day | Placebo |
12. | NORA | 2021 | Wu X, et al. (2021) [51] | III | randomized, double-blind, placebo- controlled | 265 (177/88) | Recurrent | Niraparib 100 mg three times a day | Placebo |
13. | FZOCUS-2 | 2022 | Ning Li et al. (2022) [52] | III | randomized, double-blind, placebo- controlled | 252 (167/85) | Recurrent | Fuzuloparib 150 mg orally twice a day | Placebo |
14. | ARIEL 4 | 2022 | Kristeleit et al. (2022) [53] | III | randomized, open-label | 349 (233/116) | Recurrent | Rucaparib 600 mg orally twice a day | Paclitaxel or PBC |
15. | NRG-GY004 | 2022 | Liu et al. (2022) [54] | III | randomized, open-label | 376 (189/187) | Recurrent | Olaparib 300 mg orally twice a day | PBC |
16. | Kummar 2015 | 2015 | Kummar et al. (2015) [55] | II | randomized, open-label | 75 (37/38) | Recurrent | Cyclophosphamide + Veliparib 60 mg orally tablets daily | Cyclophosphamide daily |